With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
This is an exciting role at BenevolentAI where you will apply your experience as an in vivo pharmacologist and project representative to help projects drive to achieve key milestones. As a member of a dynamic, multi-disciplinary team of scientists passionate about developing medicines, you will lead a team of project representatives and also act as project rep for projects, defining the translational strategy with in vivo PD models and target engagement.
Working collaboratively with DMPK, clinical pharmacology, modelling, In vivo and In vitro colleagues, using your theoretical and practical expertise, you’ll take a hands-on approach in the externalised development of disease models, and management of studies across the portfolio. You will supplement the analysis of results through histology, molecular and biochemical profiling. You will identify and build strong relationships with the best CROs to deliver the appropriate support for projects, build systems and deliver datasets that will have a direct impact on project progression.
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Head over to our Glassdoor page to learn about our benefits, culture and to find out what our team thinks about life at Benevolent. You can also find out more about us on LinkedIn and Twitter.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email hello@benevolent.ai. Thank you.